Cemiplimab

塞普利单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameCemiplimab
Drug Alias Name西米普利单抗Cemiplimab-rwlcLibtayoREGN-2810SAR-439684
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerSkin Melanoma +[52] 
Global Approved IndicationsUterine Cervical NeoplasmsCarcinoma, Squamous Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/09/28
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAzienda Socio Sanitaria Territoriale Degli Spedali Civili Di BresciaRadboud University Medical CenterRegeneron Ireland Designated Activity Company +[19] 
Inactive CompaniesGeorgetown UniversityWeill Medical College of Cornell UniversityThe University Of Chicago +[9] 
Active IndicationsMetastatic breast cancerSkin MelanomaOropharyngeal Squamous Cell Carcinoma (OPSCC) +[40] 
Inactive IndicationsBrain metastasesOral Squamous Cell CarcinomaProstatic Neoplasms +[12] 

Other Information

ATC CodeL01FF06L01XC33
Related LinksWikipediaDrugBankKEGG